Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis
Journal of the American Heart Association · 04.11.2025 · 14 (21)
DOI: 10.1161/jaha.125.042896 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, erschienen am 04.11.2025. Verfasst von Yuxuan Tao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine Beijing China. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Cardiovascular Diseases, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Angiogenesis inhibitors ( AIs ) are effective in cancer therapy due to their ability to suppress tumor vasculature. However, these agents are associated with significant cardiovascular toxicities, including hypertension, thrombosis, and heart failure, which may increase when combined with other cancer treatments, such as chemotherapy or immunotherapy. This meta‐analysis aims to evaluate the cardiovascular adverse events linked to AIs , focusing on their types, incidence, and severity of these adverse events to provide a clearer understanding of the cardiovascular risks associated with AIs .
Methods
A systematic review was conducted for randomized controlled trials that assessed AI therapies. The data from 64 studies involving 27 639 patients were analyzed using a random‐effects model. Major adverse cardiovascular events such as hypertension, thrombosis, arrhythmias, myocardial ischemia, and left ventricular dysfunction were the primary outcomes.
Results
The analysis revealed that AI treatment significantly increased the incidence of hypertension (relative risk [RR], 3.28 [95% CI, 2.82–4.30]), myocardial ischemia or infarction events (RR, 2.09 [95% CI, 1.05–4.17]), arrhythmia events (RR, 1.25 [95% CI, 0.90–1.74]), thrombotic events (RR, 1.46 [95% CI, 1.11–1.92]), and left ventricular dysfunction (RR, 2.00 [95% CI, 1.18–3.41]). Subgroup analyses indicated that the combination of AIs with chemotherapy or other targeted therapies heightened these risks.
Conclusions
AIs significantly increase the risk of cardiovascular events in patients with cancer, particularly when combined with other treatments. Clinicians should balance the benefits and cardiovascular risks of AIs and consider strategies to reduce these adverse effects. Further research is needed to refine these insights.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine Beijing China.
- Dongguan Hospital of Traditional Chinese Medicine Dongguan Guangdong China.
- Science and Technology Innovation Center Guangzhou University of Chinese Medicine Guangzhou Guangdong China.
ORCID-Profile: Yuxuan Tao, Weilu Cui, Wenyuan Song, Haixia Li
Zitieren
APA
Tao, Y., Cui, W., Song, W., Xu, H., Zeng, J., & Li, H. (2025). Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association, 14(21). https://doi.org/10.1161/jaha.125.042896
Vancouver
Tao Y, Cui W, Song W, Xu H, Zeng J, Li H. Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2025;14(21). doi:10.1161/jaha.125.042896
BibTeX
@article{Tao2025,
author = {Tao, Yuxuan and Cui, Weilu and Song, Wenyuan and Xu, Haotian and Zeng, Jing and Li, Haixia},
title = {Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {21},
doi = {10.1161/jaha.125.042896}
}
EUVIMED